CHESHIRE, Conn.-- -- Alexion Pharmaceuticals, Inc. announced today that it has successfully completed its previously announced acquisition of Synageva BioPharma Corp. , strengthening its global leadership in devastating and rare diseases, and creating the most robust rare disease pipeline in the biotech industry across a range of therapeutic modalities. The transaction was completed through a merger of Synageva with and into a direct, wholly owned subsidiary of Alexion.